about
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.Dasatinib first-line: Multicentric Italian experience outside clinical trials.Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalitiesu-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progressionA voluminous mass as an initial clinical symptom of multiple myeloma: A case reportFrontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Antineoplastic drug-induced bradyarrhythmias.Targeted strategies in the treatment of primary gastric lymphomas: from rituximab to recent insights into potential new drugs.Challenges and opportunities of microRNAs in lymphomas.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis.The European accreditation of Istituto Tumori Giovanni Paolo II of Bari.Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP).We have a specific duty to maximise the safety of related donorsHigh-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas.HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.Improving Provision of Care for Long-term Survivors of Lymphoma.Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study.Primary intracranial dural B cell small lymphocytic lymphomaA novel approach to evaluate blood parameters using computer vision techniquesA supervised CAD to support telemedicine in hematologySynchronous Presentation of B-Cell Chronic Lymphocytic Leukemia/Small-Cell Lymphoma and Colon Adenocarcinoma Within the Same Mesenteric Lymph Nodes and a Single Liver MetastasisEndothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myelomaPoor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantationFour proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targetsComplete response to second line Paclitaxel every 2 weeks of eyelid kaposi sarcoma: a case report
P50
Q33404090-FF008AFA-0CD3-4673-8A84-09219818BD5DQ33419053-E324D973-AAD6-4657-854E-8F472EA8AD33Q33428221-1ADD1F21-B5F8-4C0C-A092-F663077731D7Q33431829-F184D3DB-793A-4BD5-9D9D-C56392ACD0CEQ33760754-0B95E958-CC03-464D-91A0-6ED1BAF2F695Q36322476-9D61E279-5FCA-4857-9D84-638978A3CF03Q36335530-6100271C-0DCA-453F-BD1E-D11009103934Q37273788-3BB2020E-11CC-415C-934A-93D5153EF419Q37972932-DBD3A26A-0E7A-4C3B-9D49-37F774AD8CCBQ37996443-C1384442-7972-488A-90B6-0B5AD7A98912Q38025714-7A0CE7E2-4F32-4A1E-A061-7D2BCF534B8FQ38132871-5F354D04-D72F-42E3-B2F1-97442DA5ECB1Q38251994-9BA0DA7E-413D-4449-ABC4-2160266F6A64Q38554626-0B6D2DE2-0F3A-45D8-AD3A-D7A3766B0432Q38622042-9ECACD44-7278-4042-A93A-6178D4740370Q38812662-2E7D4AAD-FDEB-4F69-BA98-2A7684C5130DQ39007009-829BAC7E-5258-48F7-84EE-415F102C6D04Q40095723-E2634F11-40A6-4D5B-BEDF-C47C1D689B0AQ40144116-2F91FD85-E7B4-45FB-9176-374A07165862Q40544831-AB4276C5-0821-41A4-8B26-9CE71FB76C21Q42343632-E9F602DE-8EBF-4180-9A19-E6BAB9DD2F2CQ43274038-466D7652-20F9-48C8-9924-B76961DCDD1CQ43584641-3E8406FE-09D2-4348-9F11-055BD5ED635FQ44563437-3308A398-08AF-4257-A96C-C3C73059FD61Q45140129-27B5E7BA-9F8E-4A6A-976C-192EFAEE2269Q47654723-7A09F41C-986A-4CE3-B027-DD4216DC17B9Q50064085-77F02A53-7989-4205-96CE-AC7E1D706866Q51412158-CEAC7F4D-0E5C-4B30-8FA0-E6651C1D4BB1Q52991094-BB206C61-CAA5-4BFC-B4BD-25FA008A4443Q53377096-417628A2-56CD-4EBA-9B6D-FC6E49CAC966Q54614177-1063075D-4AE2-4D9C-A771-A8BC98E46EECQ55047627-F22D0219-6DB8-4715-899D-03A2CBC55D57Q57998940-5454285D-70AD-4E2B-9358-8ADFE0370F18Q58225366-560977AC-6F03-4121-B375-1D4682B29BCCQ58225381-EAD7B816-CB09-4E75-8E2D-F8441C278D6BQ60170550-C402CA67-4222-4329-B26A-EF886D5E0B2EQ80888975-54BA8DF1-27AF-4A7C-B2F6-3648A55402D0Q82735571-50E791E8-4708-4ED4-9D2C-317375CD068FQ85026964-1BA8FEDD-30B8-451D-A735-2FCDF27CD2B2Q85711696-F4A438AB-E7A3-4835-98C2-88F181D1F56C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Attilio Guarini
@ast
Attilio Guarini
@en
Attilio Guarini
@es
Attilio Guarini
@nl
type
label
Attilio Guarini
@ast
Attilio Guarini
@en
Attilio Guarini
@es
Attilio Guarini
@nl
prefLabel
Attilio Guarini
@ast
Attilio Guarini
@en
Attilio Guarini
@es
Attilio Guarini
@nl
P106
P1153
7004283613
P31
P496
0000-0002-9304-6651